Literature DB >> 21371091

Characterization of the complex between mannose-binding lectin trimer and mannose-binding lectin-associated serine proteases.

Koichiro Tateishi1, Takahiro Kanemoto, Teizo Fujita, Misao Matsushita.   

Abstract

Mannose-binding lectin (MBL) is an oligomeric serum lectin involved in innate immunity. Human MBL is complexed with three types of serine proteases (MASP-1, MASP-2 and MASP-3) and two types of their truncated forms (sMAP and MAp44). When an MBL complex binds to carbohydrates of pathogens, the complement system is activated via the lectin pathway. Human MBL is a mixture of different sized oligomers that range mainly from trimers to hexamers. It has been suggested that different MBL oligomers may have distinct MASP compositions. In the present study, an MBL trimer (MBL-I) exclusive of other oligomers was isolated from human serum by chromatography. Immunoblot analysis of MBL-I revealed that it had been co-purified with MASP-1 and sMAP. This suggests that MASP-1 and sMAP are bound to each other in MBL-I. The MBL-I complex was found to activate C2, but to lack the ability to activate C4 due to the absence of MASP-2.
© 2011 The Societies and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371091     DOI: 10.1111/j.1348-0421.2011.00330.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  3 in total

Review 1.  Mannose-binding lectin and the balance between immune protection and complication.

Authors:  Kazue Takahashi
Journal:  Expert Rev Anti Infect Ther       Date:  2011-12       Impact factor: 5.091

2.  Mannose-binding lectin binds to amyloid β protein and modulates inflammation.

Authors:  Mykol Larvie; Timothy Shoup; Wei-Chuan Chang; Lorencia Chigweshe; Kevan Hartshorn; Mitchell R White; Gregory L Stahl; David R Elmaleh; Kazue Takahashi
Journal:  J Biomed Biotechnol       Date:  2012-03-27

Review 3.  Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.

Authors:  Jack Mellors; Tom Tipton; Stephanie Longet; Miles Carroll
Journal:  Front Immunol       Date:  2020-07-09       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.